Synthesis, Pharmacological and Structural Characterization, and Thermodynamic Aspects of GluA2-Positive Allosteric Modulators with a 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxide Scaffold
摘要:
Positive allosteric modulators of ionotropic glutamate receptors are potential compounds for treatment of cognitive disorders, e.g., Alzheimer's disease. The modulators bind within the dimer interface of the ligand-binding domain (LBD) and stabilize the agonist-bound conformation, thereby slowing receptor desensitization and/or deactivation. Here we describe the synthesis and pharmacological testing at GluA2 of a new generation of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides. The most potent modulator 3 in complex with GluA2-LBD-L483Y-N754S was subjected to structural analysis by X-ray crystallography, and the thermodynamics of binding was studied by isothermal titration calorimetry. Compound 3 binds to GluA2-LBD-L483Y-N754S with a K-d of 0.35 mu M (Delta H = -7.5 kcal/mol and -T Delta S = -1.3 kcal/mol). This is the first time that submicromolar binding affinity has been achieved for this type of positive allosteric modulator. The major structural factor increasing the binding affinity of 3 seems to be interactions between the cyclopropyl group of 3 and the backbone of Phe495 and Met496.
Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them
申请人:FRANCOTTE Pierre
公开号:US20100009974A1
公开(公告)日:2010-01-14
Compounds of formula (I):
wherein:
R
Cy
represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group,
R
1
, R
2
, R
3
and R
4
, which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group.
Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.
Nouveaux dérivés de benzothiadiazines cycloalkylées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
申请人:Les Laboratoires Servier
公开号:EP2147915B1
公开(公告)日:2010-09-15
US7741320B2
申请人:——
公开号:US7741320B2
公开(公告)日:2010-06-22
[EN] NEW CYCLOALKYLATED BENZOTHIADIAZINE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DERIVES DE BENZOTHIADIAZINES CYCLOALKYLEES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
申请人:SERVIER LAB
公开号:WO2010004139A1
公开(公告)日:2010-01-14
Composés de formule (I) dans laquelle Rcy représente un groupement cycloalkyle ou un groupement cycloalkylalkyle non- substitué ou substitué, R1, R2, R3 et R4, identiques ou différents, représentent chacun un atome d'hydrogène ou d'halogène ou un groupement nitro; cyano; hydroxy; alkoxy; alkyle; amino non-substitué ou substitué; carboxy; alkoxycarbonyle; loxycarbonyle; aminocarbonyle non-substitué ou substitué.
Synthesis, Pharmacological and Structural Characterization, and Thermodynamic Aspects of GluA2-Positive Allosteric Modulators with a 3,4-Dihydro-2<i>H</i>-1,2,4-benzothiadiazine 1,1-Dioxide Scaffold
Positive allosteric modulators of ionotropic glutamate receptors are potential compounds for treatment of cognitive disorders, e.g., Alzheimer's disease. The modulators bind within the dimer interface of the ligand-binding domain (LBD) and stabilize the agonist-bound conformation, thereby slowing receptor desensitization and/or deactivation. Here we describe the synthesis and pharmacological testing at GluA2 of a new generation of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides. The most potent modulator 3 in complex with GluA2-LBD-L483Y-N754S was subjected to structural analysis by X-ray crystallography, and the thermodynamics of binding was studied by isothermal titration calorimetry. Compound 3 binds to GluA2-LBD-L483Y-N754S with a K-d of 0.35 mu M (Delta H = -7.5 kcal/mol and -T Delta S = -1.3 kcal/mol). This is the first time that submicromolar binding affinity has been achieved for this type of positive allosteric modulator. The major structural factor increasing the binding affinity of 3 seems to be interactions between the cyclopropyl group of 3 and the backbone of Phe495 and Met496.